Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide

British Journal of Haematology

Volumn 113, Issue 2, 2001, Pages 339-346

  Lotfi, Kourosh ^a   Månsson, Emma ^a   Chandra, Joya ^b   Wang, Yuying ^c   Xu, Dawei ^d   Knaust, Eva ^e   Spasokoukotskaja, Tatjana ^f   Liliemark, Eva ^g   Eriksson, Staffan ^a   Albertioni, Freidoun ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b Department of Medicine   (Sweden)

^c Department of Oncology Pathology ^*  (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e MAYO CLINIC   (United States)

^f SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^g SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

5 nucleotidase; CD95; Cladribine; Deoxycytidine kinase; Etoposide

Indexed keywords

5' NUCLEOTIDASE; CLADRIBINE; CYTARABINE; DAUNORUBICIN; DEOXYCYTIDINE KINASE; DEOXYRIBONUCLEOSIDE TRIPHOSPHATE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FAS LIGAND; GEMCITABINE; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NEBULARINE; NUCLEOTIDE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CROSS RESISTANCE; ENZYME ACTIVITY; ENZYME DEGRADATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LYMPHATIC LEUKEMIA; PRIORITY JOURNAL;

5'-NUCLEOTIDASE; BLOTTING, WESTERN; CELL LINE; CLADRIBINE; CYTARABINE; DEOXYCYTIDINE KINASE; DEOXYCYTOSINE NUCLEOTIDES; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MICROBIAL; ETOPOSIDE; FAS LIGAND PROTEIN; GENES, MDR; HUMANS; ISOENZYMES; LEUKEMIA, T-CELL, ACUTE; MEMBRANE GLYCOPROTEINS;

EID: 0035004335     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2001.02751.x     Document Type: Article

References (41)

1. Techniques to measure DNA single-strand breaks in cells: A review
2. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II
3. Common regulation of apoptosis signaling induced by CD95 and the DNA-damaging stimuli etoposide and gamma-radiation downstream from caspase-8 activation
4. Etoposide: An update
5. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells
6. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease
7. Characterization of newly established human myeloid leukemia cell line (KF-19) and its drug resistant sublines
8. Induction of human high K (M) 5′-nucleotidase in cultured 293 cells
9. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway
10. Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-beta-D- arabinofuranosylcytosine
11. 2′,2′-difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA)
12. The role of topoisomerase II alpha and beta in drug resistance
13. The clinical pharmacology of etoposide: An update
14. Ribonucleotide reductases
15. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine
16. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine
17. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin
18. Cellular resistance to topoisomerase-targeted drugs: From drug uptake to cell death
19. Multidrug resistance in leukemia
20. Altered drug sensitivity in response to idarubicin treatment in K562 human leukaemia cells
21. Biochemical pharmacology and resistance to 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, a novel analogue of cladribine in human leukemic cells
22. DNA damage signals induction of fas ligand in tumor cells
23. Nucleosomes contain DNA binding proteins that resist dissociation by sodium dodecyl sulfate
24. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line
25. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis
26. 2-Chloro-2′-deoxyadenosine induces apoptosis through the Fas/Fas ligand pathway in human leukemia cell line MOLT-4
27. Pharmacology of purine nucleoside analogues
28. Simultaneous determination of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and 3-deazauridine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography
29. Determination of 2-chloro-2′-deoxyadenosine nucleotides in leukemic cells by ion-pair high-performance liquid chromatography
30. 2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders
31. DNA damage by antitumor acridines mediated by mammalian DNA topoisomerase II
32. Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity
33. Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers
34. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues
35. Regulation of low Km (ecto-) 5′-nucleotidase gene expression in leukemic cells
36. Expression of Fas/APO-1 during the progression of astrocytomas
37. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells
38. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells
39. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation
40. Etoposide-induced DNA strand breaks in relation to p-glycoprotein and topoisomerase II protein expression in leukaemic cells from patients with AML and CLL
41. Topoisomerase II-mediated alterations of K562 drug resistant sublines